Page last updated: 2024-09-05

dabigatran and Embolus

dabigatran has been researched along with Embolus in 136 studies

Research

Studies (136)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (2.21)	29.6817
2010's	99 (72.79)	24.3611
2020's	34 (25.00)	2.80

Authors

Authors	Studies
Alioğlu, E; Altın, C; Bilgin, N; Çetin, N; Dalgıç, O; Ekmekçi, C; Kocabaş, U; Özpelit, ME; Pekel, N; Topaloğlu, C; Tülüce, K; Tunçer, E; Türk, UÖ; Türkoğlu, Eİ; Yavuz, V; Yüksel, K	1
de Vries, TI; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; Visseren, FLJ; Westerink, J	1
Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y	1
Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Uchiyama, S; Wakayama, J; Yamashita, T; Yasaka, M	1
Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q	1
Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK	1
Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H	1
Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H	1
Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y	1
Altın, C; Aslan, O; Bilgel, ZG; Boyraz, B; Çakal, S; Çayırlı, S; Çoner, A; Coşgun, MS; Dal, A; Dalgıç, O; Demir, M; Doğduş, M; Erdoğan, A; Ergin, I; Genç, Ö; Güler, A; Güvendi Şengör, B; İbişoğlu, E; İlkay Yüce, E; Kaplan, M; Karabulut, D; Karabulut, U; Keskin Meriç, B; Kıvrak, T; Kocabaş, U; Murat, B; Murat, S; Naki Tekin, DD; Özçalık, E; Özdemir, I; Özgeyik, M; Özyurtlu, F; Şahin, Ş; Şen, T; Tüner, H; Urgun, ÖD; Uzman, O; Yavuz, V	1
Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH	1
Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E	1
Brinkmann, M; Diener, HC; Eschenfelder, CC; Gröschel, K; Grosse, GM; Hüsing, A; Kuklik, N; Michalski, D; Nabavi, D; Poli, S; Royl, G; Sparenberg, P; Stang, A; Weimar, C; Weissenborn, K	1
Alt, E; Bessette, LG; Kim, DH; Mahesri, M; Najafzadeh, M; Schneeweiss, S; Shin, H; Wang, SV	1
An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K	1
Chan, YH; Fong, KY; Lip, GYH; Tan, VH; Yeo, C	1
Huang, KC; Lee, JK; Lin, DS; Lin, TT; Lo, HY	1
Chu, YB; Dong, SJ; Gupta, P; Li, YH; Wu, B; Zhai, SD; Zhang, YJ	1
Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F	2
Huang, Y; Liang, H; Rong, G; Wang, H; Wang, L	1
Prabha, N; Singh, A; Yadav, H	1
Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Falissard, B; Gollety, S; Hanon, O; Jacoud, F; Lefevre, C; Mahé, I; Nolin, M; Steg, PG; Van Ganse, E	1
Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J	1
Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP	1
Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A	1
Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM	1
Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N	1
Chutinet, A; Diener, HC; Easton, JD; Granger, CB; Kleine, E; Marquardt, L; Meyerhoff, J; Sacco, RL; Zini, A	1
Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H	1
Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S	1
Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD	1
Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C	1
Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM	1
Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS	1
Chan, KA; Chen, HM; Lai, CL; Liao, MT; Lin, TT	1
Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE	1
Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q	1
Cao, Q; Jacobs, MS; Jansman, FGA; Postma, MJ; Tieleman, RG; van Hulst, M; van Leent, MWJ	1
Hernandez, I; Saba, S; Zhang, Y	1
Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M	1
Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ	1
Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L	1
Jesus, PAP; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG	1
Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S	1
Kyle, A; McBain, L	1
Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L	1
Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J	1
Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H	1
Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM	1
Aljohani, MM; Alsager, OA; Chinnappan, R; Cialla-May, D; Eissa, S; Popp, J; Weber, K; Zourob, M	1
Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N	1
Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB	1
Eto, A; Hiraoka, F; Nii, K; Tsutsumi, M	1
Hirakawa, T; Ishida, K; Koretsune, Y; Kuroki, D; Ono, Y; Sumida, T; Urushihara, H; Yamashita, T; Yasaka, M	1
Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT	1
Rubboli, A	1
Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Taniguchi, A; Uchiyama, S; Yamashita, T; Yasaka, M	1
Aonuma, K; Goya, M; Harada, T; Hirao, K; Kihara, Y; Nakahara, S; Nakano, Y; Nogami, A; Nuruki, N; Origasa, H; Otani, R; Sekiguchi, Y; Yoshida, K; Yoshida, Y	1
Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H	1
Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L	1
Hinotsu, S; Kano, MR; Kitamura, Y; Koyama, T; Miller, MW; Ogawa, A; Ohshima, A; Sendo, T; Tanaka, HY; Zamami, Y	1
Dalmau, FG	1
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C	1
Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N	1
Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD	1
Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP	1
Ahmad, Y; Lip, GY	2
Verheugt, FW	1
Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J	1
Baglin, T	1
Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S	1
Adam, G; Akbal, E; Asik, M; Bilen, Oİ; Binnetoglu, E; Gunes, F; Sen, H; Temiz, A; Ukinc, K	1
Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S	1
Chang, CH; Chen, JH; Lin, LJ; Yang, YH	1
Cordova, EG; del Aguila, D; Salazar, CA	1
Hürlimann, D; Noll, G; Noll, S	1
Expósito, V; Fernández-Fresnedo, G; Seras, M	1
Banfi, R; Fallani, F; Palazzi, N; Pugi, A	1
Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y	1
Beyer-Westendorf, J; Daschkow, K; Ebertz, F; Endig, H; Förster, K; Gelbricht, V; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Tittl, L; Weiss, N; Werth, S	1
Eikelboom, JW; Weitz, JI	1
Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH	1
Ageno, W; Riva, N	1
Marietta, M	1
Connolly, SJ; Ezekowitz, MD; Fukaya, T; Hori, M; Kleine, E; Reilly, PA	1
Fujikawa, T; Imagawa, A; Ueta, E	1
Demir, S; Kendirli, MT; Ozdag, MF; Togrol, RE	1
Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D	1
Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD; Zint, K	1
Shaw, P; Wood, M	1
Eikelboom, J; Weitz, JI	1
Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S	1
Dagres, N; Hindricks, G; Jokic, V; Lane, DA; Larsen, TB; Lip, GY; Potpara, TS	1
Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C	1
Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L	1
Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y	1
Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F	1
Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B	1
Aisenberg, J; Brueckmann, M; Chatterjee, P; Connolly, S; Desai, J; Ezekowitz, M; Flack, KF; Ilgenfritz, J; Kolb, JM; Reilly, P; Wallentin, LC; Yusuf, S	1
Bhatt, DL; Vaduganathan, M	1
Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J	1
Vojácek, J	1
Ibrahim, S; Jespersen, J; Poller, L	1
Connolly, SJ; Ezekowitz, MD; Reilly, PA; Wallentin, L; Yusuf, S	1
Thompson, CA	1
Neilson, RF	1
Aikens, TH; Chernick, MR; Connolly, SJ; Ezekowitz, MD; Lip, GY; Parekh, A; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S	1
Garnock-Jones, KP	1
Eikelboom, JW; Haroun, MJ; Paikin, JS	1
Beasley, BN; Temple, R; Unger, EF	1
Belavic, JM	1
Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C	1
Bartholomew, JR; Wartak, SA	1
Yates, SW	1
Kamal, AK; Khan, M; Raza, E	1
Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S	1
Cowie, MR; Gani, R; Kansal, AR; Pan, F; Plumb, JM; Robinson, P; Sorensen, SV	1
Wise, J	1
Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C	1
Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A	1
McKeage, K	1
Ansell, J; Mantha, S	1
Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L	1
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S	1
Fareed, J; Kalodiki, E; Lewis, B	1
Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C	1
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV	1
Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC	1
Barrios, V; Escobar, C	1
Sinnaeve, PR; Van de Werf, F	1
Brueckmann, M; Connolly, SJ; Dans, AL; Eikelboom, JW; Ezekowitz, M; Nakamya, J; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S	1
Annemans, L; Thijs, V; Wouters, H	1
Sarah, S	1

Reviews

33 review(s) available for dabigatran and Embolus

Article	Year
Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk. The American journal of cardiology, 2023, 10-01, Volume: 204 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Risk Factors; Stroke; Treatment Outcome; Warfarin	2023
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2023, Dec-05, Volume: 12, Issue:23 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke	2023
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article. Medicine, 2020, Jul-02, Volume: 99, Issue:27 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin	2020
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis. The American journal of cardiology, 2021, 03-01, Volume: 142 Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin	2021
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. The American journal of medicine, 2017, Volume: 130, Issue:9 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin	2017
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane database of systematic reviews, 2017, Nov-06, Volume: 11 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. Journal of oncology practice, 2017, Volume: 13, Issue:11 Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 02-01, Volume: 34, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2019
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. European journal of epidemiology, 2019, Volume: 34, Issue:2 Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome	2019
Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial. Medicine, 2018, Volume: 97, Issue:46 Topics: Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin	2018
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 07-16, Volume: 8, Issue:14 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2019
[The new oral anticoagulants in special populations]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis	2012
[Improvements in oral anticoagulant therapy for atrial fibrillation]. Medicina clinica, 2013, Dec-07, Volume: 141, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin	2013
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. PharmacoEconomics, 2013, Volume: 31, Issue:7 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Humans; Quality-Adjusted Life Years; Stroke; Technology Assessment, Biomedical	2013
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin	2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation. Contributions to nephrology, 2013, Volume: 179 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin	2013
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. British journal of haematology, 2013, Volume: 163, Issue:2 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes	2013
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1 Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2014
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. The Cochrane database of systematic reviews, 2014, Mar-27, Issue:3 Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin	2014
[Oral anticoagulation in chronic kidney disease with atrial fibrillation]. Medicina clinica, 2015, May-21, Volume: 144, Issue:10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke	2015
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and haemostasis, 2016, Volume: 115, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. Current medicinal chemistry, 2016, Volume: 23, Issue:19 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Renal Insufficiency, Chronic; Stroke; Warfarin	2016
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. Current medical research and opinion, 2016, Volume: 32, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin	2016
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC. Heart failure, 2016, Volume: 4, Issue:11 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2016
Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Current neurology and neuroscience reports, 2012, Volume: 12, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin	2012
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Hospital practice (1995), 2011, Volume: 39, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin	2011
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. PharmacoEconomics, 2012, Sep-01, Volume: 30, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Embolism; Humans; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin	2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin	2012
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2012
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18 Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Evidence-Based Medicine; Hemorrhage; Humans; Risk Factors; Stroke	2012
The pharmacology and therapeutic use of dabigatran etexilate. Journal of clinical pharmacology, 2013, Volume: 53, Issue:1 Topics: Antithrombins; Benzimidazoles; Dabigatran; Drug Interactions; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke	2013

Trials

16 trial(s) available for dabigatran and Embolus

Article	Year
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. Clinical pharmacology and therapeutics, 2023, Volume: 114, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Stroke; Treatment Outcome; United States; Warfarin	2023
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. PloS one, 2020, Volume: 15, Issue:11 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin	2020
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. Stroke, 2021, Volume: 52, Issue:3 Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolism; Female; Foramen Ovale, Patent; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Young Adult	2021
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time	2019
Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial. JAMA network open, 2019, 04-05, Volume: 2, Issue:4 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Perioperative Period; Prospective Studies; Thromboembolism; Treatment Outcome; Warfarin	2019
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, Jul-16, Volume: 128, Issue:3 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Stroke; Treatment Outcome	2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4 Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes Mellitus; Embolism; Female; Hemorrhage; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Stroke	2014
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation, 2014, Mar-04, Volume: 129, Issue:9 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin	2014
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:10 Topics: Aged; Asian People; Creatinine; Dabigatran; Embolism; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Stroke; Warfarin	2015
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thrombosis and haemostasis, 2016, 05-02, Volume: 115, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor VIIa; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prognosis; Risk Factors; Stroke; Warfarin	2016
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemoprevention; Dabigatran; Embolism; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Prevalence; Prospective Studies; Stroke; Warfarin	2017
Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 2009, Sep-17, Volume: 361, Issue:12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Dyspepsia; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Liver; Male; Middle Aged; Myocardial Infarction; Prodrugs; Proportional Hazards Models; Pyridines; Stroke; Warfarin	2009
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation, 2010, Nov-30, Volume: 122, Issue:22 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyridines; Risk Factors; Stroke; Treatment Outcome; Vitamin K; Warfarin	2010
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:3 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Follow-Up Studies; Humans; Prospective Studies; Pyridines; Risk Factors; Stroke; Vitamin K; Warfarin	2011
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (British Cardiac Society), 2012, Volume: 98, Issue:7 Topics: Aged, 80 and over; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Female; Follow-Up Studies; Humans; Male; Models, Economic; Pyridines; Stroke; United Kingdom	2012
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation, 2013, Feb-05, Volume: 127, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin	2013

Other Studies

87 other study(ies) available for dabigatran and Embolus

Article	Year
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:8 Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Sex Factors; Stroke; Thromboembolism; Turkey	2021
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making. Journal of the American Heart Association, 2022, 01-04, Volume: 11, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Embolism; Hemorrhage; Humans; Risk Factors; Stroke; Warfarin	2022
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. Journal of thrombosis and thrombolysis, 2022, Volume: 54, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin	2022
Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2. Journal of cardiology, 2022, Volume: 80, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Japan; Stroke	2022
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis. Current medical research and opinion, 2022, Volume: 38, Issue:12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin	2022
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. Annals of internal medicine, 2022, Volume: 175, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States	2022
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study. European journal of internal medicine, 2023, Volume: 108 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin	2023
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity. Advances in therapy, 2023, Volume: 40, Issue:3 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin	2023
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation, 2023, 03-07, Volume: 147, Issue:10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin	2023
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2023, Volume: 51, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Vitamin K; Young Adult	2023
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients. International journal of stroke : official journal of the International Stroke Society, 2023, Volume: 18, Issue:8 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin	2023
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. Annals of internal medicine, 2023, Volume: 176, Issue:6 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States	2023
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study. International journal of stroke : official journal of the International Stroke Society, 2023, Volume: 18, Issue:10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Prospective Studies; Stroke; Vitamins	2023
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk. Clinical therapeutics, 2023, Volume: 45, Issue:7 Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Embolism; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome	2023
Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. Clinical therapeutics, 2020, Volume: 42, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Treatment Outcome	2020
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. European heart journal. Cardiovascular pharmacotherapy, 2020, 04-01, Volume: 6, Issue:2 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome	2020
Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation. Heart and vessels, 2020, Volume: 35, Issue:7 Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Stroke; Time Factors; Treatment Outcome	2020
A Rare Case Report of Dabigatran Induced Oral Ulcers. Current drug safety, 2020, Volume: 15, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Embolism; Female; Humans; Oral Ulcer	2020
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke, 2020, Volume: 51, Issue:7 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Warfarin	2020
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention. Clinical drug investigation, 2020, Volume: 40, Issue:11 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke	2020
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation. International heart journal, 2020, Sep-29, Volume: 61, Issue:5 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures	2020
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. The American journal of cardiology, 2021, 06-01, Volume: 148 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin	2021
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). The American journal of cardiology, 2021, 06-15, Volume: 149 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin	2021
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. Annals of internal medicine, 2021, Volume: 174, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin	2021
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart (British Cardiac Society), 2022, Volume: 108, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin	2022
Acta medica Philippina, 2017, Volume: 51, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy	2017
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation. The American journal of cardiology, 2021, 08-01, Volume: 152 Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin	2021
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. European heart journal. Quality of care & clinical outcomes, 2022, 08-17, Volume: 8, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin	2022
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. Journal of the American Heart Association, 2017, Apr-24, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Transfusion; Cause of Death; Comparative Effectiveness Research; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Logistic Models; Male; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke	2017
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current medical research and opinion, 2017, Volume: 33, Issue:9 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin	2017
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands. Journal of medical economics, 2017, Volume: 20, Issue:12 Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Embolism; Female; Hemorrhage; Hospital Charges; Humans; Male; Middle Aged; Netherlands; Propensity Score; Retrospective Studies; Sex Factors; Stroke	2017
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. The American journal of cardiology, 2017, Nov-15, Volume: 120, Issue:10 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin	2017
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting. Current medical research and opinion, 2018, Volume: 34, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin	2018
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke. Arquivos de neuro-psiquiatria, 2018, Volume: 76, Issue:1 Topics: Aged; Anticoagulants; Brain Ischemia; Chagas Cardiomyopathy; Dabigatran; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Stroke; Warfarin	2018
Renal function monitoring in patients prescribed dabigatran in the Compass Health Primary Health Organisation: a quality improvement audit. The New Zealand medical journal, 2018, 03-09, Volume: 131, Issue:1471 Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Kidney Function Tests; Male; Medical Audit; Middle Aged; Quality Improvement; Stroke; Young Adult	2018
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. Medicina clinica, 2018, 09-14, Volume: 151, Issue:5 Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. The American journal of medicine, 2018, Volume: 131, Issue:9 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin	2018
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. International journal of cardiology, 2018, Oct-01, Volume: 268 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome	2018
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate. Scientific reports, 2018, 09-05, Volume: 8, Issue:1 Topics: Anticoagulants; Aptamers, Nucleotide; Atrial Fibrillation; Dabigatran; Embolism; Gene Library; Hemorrhage; Humans; Ligands; SELEX Aptamer Technique; Sensitivity and Specificity; Stroke	2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation. British journal of clinical pharmacology, 2019, Volume: 85, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; Vitamin K	2019
[A Case of Successful Drug Management with Dabigatran and Idarucizumab to Address Embolic and Hemorrhagic Complications for Asymptomatic and Traumatic Subdural Hematoma with Non-valvular Atrial Fibrillation]. No shinkei geka. Neurological surgery, 2018, Volume: 46, Issue:11 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Embolism; Female; Hematoma, Subdural; Humans	2018
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis. Journal of cardiology, 2019, Volume: 73, Issue:3 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Embolism; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Treatment Outcome; Warfarin	2019
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice. European journal of internal medicine, 2019, Volume: 62 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles	2019
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. Journal of cardiology, 2019, Volume: 73, Issue:6 Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Stroke; Thromboembolism; Time Factors; Treatment Outcome	2019
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Journal of the American Geriatrics Society, 2019, Volume: 67, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin	2019
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Family practice, 2019, 11-18, Volume: 36, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke; Warfarin; Young Adult	2019
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3 Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin	2013
New oral anticoagulants in atrial fibrillation forever? Circulation, 2013, Jul-16, Volume: 128, Issue:3 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Stroke	2013
Gastrointestinal bleeding associated with dabigatran in a patient with panhypopituitarism. Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:1-2 Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Embolism; Female; Gastrointestinal Hemorrhage; Humans; Hypopituitarism; Treatment Outcome	2014
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Thrombosis research, 2014, Volume: 133, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Markov Chains; Pyridines; Stroke; Taiwan; Warfarin	2014
Direct oral anticoagulants in atrial fibrillation. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. Recenti progressi in medicina, 2014, Volume: 105, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hemorrhage; Hospitals, General; Humans; Italy; Male; Middle Aged; Retrospective Studies	2014
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clinical therapeutics, 2014, Dec-01, Volume: 36, Issue:12 Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin	2014
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thrombosis and haemostasis, 2015, Volume: 113, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Embolism; Female; Germany; Hemorrhage; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome	2015
'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thrombosis and haemostasis, 2015, Volume: 113, Issue:6 Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Ischemic Attack, Transient; Male; Stroke	2015
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis. PloS one, 2015, Volume: 10, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin	2015
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes. Internal and emergency medicine, 2015, Volume: 10, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Europe; Female; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; United States; Warfarin	2015
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No. Internal and emergency medicine, 2015, Volume: 10, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin	2015
A case of a slightly symptomatic exfoliative oesophagitis. BMJ case reports, 2015, Aug-14, Volume: 2015 Topics: Aged; Antithrombins; Coronary Vessels; Dabigatran; Drug Therapy, Combination; Embolism; Esophagitis; Esophagus; Humans; Lansoprazole; Male; Proton Pump Inhibitors	2015
What Do Anticoagulants Say about Microemboli? Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Warfarin	2015
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting. Clinical drug investigation, 2015, Volume: 35, Issue:11 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin	2015
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Evaluation; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Insurance Coverage; Male; Middle Aged; Myocardial Infarction; Polypharmacy; Propensity Score; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult	2015
Pradaxa-induced esophageal ulcer. BMJ case reports, 2015, Oct-09, Volume: 2015 Topics: Aged; Anticoagulants; Dabigatran; Embolism; Endoscopy, Gastrointestinal; Esophageal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Stomach; Ulcer; Warfarin	2015
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. Journal of the American Heart Association, 2016, 05-04, Volume: 5, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin	2016
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Journal of cardiology, 2017, Volume: 69, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin	2017
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ (Clinical research ed.), 2016, Jun-16, Volume: 353 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin	2016
Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Gastrointestinal Hemorrhage; Humans; Neoplasms; Stroke; Warfarin	2017
[The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation]. Vnitrni lekarstvi, 2009, Volume: 55, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Warfarin	2009
Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 2009, Dec-31, Volume: 361, Issue:27 Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Hemorrhage; Humans; Incidence; International Normalized Ratio; Pyridines; Stroke; Warfarin	2009
Newly identified events in the RE-LY trial. The New England journal of medicine, 2010, Nov-04, Volume: 363, Issue:19 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Pyridines	2010
First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, Dec-01, Volume: 67, Issue:23 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Monitoring; Embolism; Humans; International Normalized Ratio; Pyridines; Stroke; Thrombin	2010
Warfarin: is the end nigh? Please? The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin	2010
Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Volume: 11, Issue:1 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Economics, Pharmaceutical; Embolism; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Stroke	2011
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin	2011
Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation. The Nurse practitioner, 2011, Volume: 36, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Embolism; Humans; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin	2011
Dabigatran: will it change clinical practice? Cleveland Clinic journal of medicine, 2011, Volume: 78, Issue:10 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin	2011
What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis? JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:6 Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Evidence-Based Medicine; Humans; International Normalized Ratio; Pakistan; Pyridines; Stroke; Treatment Outcome; Warfarin	2011
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. Journal of the American College of Cardiology, 2012, Feb-28, Volume: 59, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin	2012
NICE backs new oral anticoagulant for stroke prevention. BMJ (Clinical research ed.), 2012, Mar-16, Volume: 344 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke	2012
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. Vascular and endovascular surgery, 2012, Volume: 46, Issue:4 Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency	2012
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart (British Cardiac Society), 2012, Volume: 98, Issue:19 Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Guideline Adherence; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome	2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2012
New oral anticoagulant in atrial fibrillation: are they comparable? International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thrombosis and haemostasis, 2012, Volume: 108, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Revista espanola de cardiologia (English ed.), 2012, Volume: 65, Issue:10 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin	2012
Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets. Circulation, 2013, Feb-05, Volume: 127, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Female; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Stroke; Warfarin	2013
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. Journal of medical economics, 2013, Volume: 16, Issue:3 Topics: Adult; Aged; Atrial Fibrillation; Belgium; Benzimidazoles; Confidence Intervals; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Middle Aged; Pyridines; Quality-Adjusted Life Years; Stroke	2013